CONTACT US   |  (864) 397-5101

Could leaky blood vessels in the brain be a culprit in Alzheimer’s disease?

Compliments of MUSC Catalyst News

Alzheimer’s disease is an enormous problem that, with an aging population, will only become bigger. More than 6 million Americans are living with Alzheimer’s disease, and 1 in 3 seniors will die of it, according to the Alzheimer’s Association. By 2050, the cost of Alzheimer’s disease, currently estimated at $355 billion, will rise to $1.1 trillion.

Could one of the causes of such a huge and costly problem be traced back to the cells that line the body’s tiniest blood vessels?

A new study published by a Medical University of South Carolina (MUSC) research team in Molecular Therapy suggests that the answer is yes.  The team, led by Hongkuan Fan, Ph.D., associate professor in the Department of Pathology and Laboratory Medicine, found fewer of these cells, known as pericytes, in the brains of people who died of Alzheimer’s disease. They also found higher levels of Fli-1, a protein most often found in blood cells and thought to govern their development.  

When the team blocked, or inhibited, the action of Fli-1 in a mouse model of Alzheimer’s disease, the memory of the mice improved. Blocking the protein also stopped immune cells from leaking into the brain and causing the inflammation that is a hallmark of Alzheimer’s disease. Blocking Fli-1 could be a promising new approach to treating Alzheimer’s disease and other dementias. Click to continue enjoying the complete article.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.